论文部分内容阅读
目的观察妈咪爱和思密达联合佐治新生儿高胆红素血症的疗效,以更好地预防核黄疸。方法 90例新生儿高胆红素血症患儿,随机分为常规治疗组(40例)及联合治疗组(50例)。常规治疗组采用常规治疗。联合治疗组在常规治疗的基础上,给予妈咪爱和思密达联合治疗,比较两组的疗效。结果常规治疗组首日胆红素下降值为(41.54±31.98)μmol/L,明显少于联合治疗组的(59.98±51.52)μmol/L(t=2.79,P<0.05);常规治疗组每日平均胆红素下降值为(38.98±22.59)μmol/L,明显少于联合治疗组的(58.95±26.69)μmol/L(t=4.35,P<0.05);常规治疗组胆红素值下降至<110μmol/L时间为(6.3±4.2)d,明显长于联合治疗组的(4.4±2.5)d(t=3.64,P<0.05)。结论妈咪爱和思密达联合佐治新生儿高胆红素血症可获得良好疗效,使血清胆红素水平快速下降,明显减少了患儿的住院治疗时间,从而减轻患儿家长的经济负担。
Objective To observe the effects of mommy and smecta adjuvant treatment of neonatal hyperbilirubinemia in order to better prevent kernicterus. Methods Ninety neonates with hyperbilirubinaemia were randomly divided into routine treatment group (n = 40) and combination therapy group (n = 50). The conventional treatment group used routine treatment. Combination therapy group on the basis of routine treatment, given Mommy love and Smecta combination therapy, the efficacy of the two groups were compared. Results The decrease of bilirubin in the first treatment group was (41.54 ± 31.98) μmol / L less than that in the combined treatment group (59.98 ± 51.52 μmol / L, t = 2.79, P <0.05) The mean daily bilirubin level was (38.98 ± 22.59) μmol / L, which was significantly lower than that of the combined treatment group (58.95 ± 26.69 μmol / L, t = 4.35, P <0.05) (6.3 ± 4.2) d to <110μmol / L, which was significantly longer than that of the combined treatment group (4.4 ± 2.5) d (t = 3.64, P <0.05). Conclusion Mami love and Smectite combined adjuvant treatment of neonatal hyperbilirubinemia can obtain good curative effect, so that serum bilirubin levels decreased rapidly, significantly reduce the hospitalization of children with treatment time, thereby reducing the financial burden on parents of children .